Therapeutic or Preventive Procedure

Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme

13 hours ago talkbio0Tagged ALT-positive, Boehringer, cellular targeting, Ingelheim, Malignant Neoplasms

Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

20 hours ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country

2 days ago talkbio0Tagged Expanding, expansion, Indiana, Investments, Pennsylvania, Research Organization, Roche (company), United States, Upgrade

Roche (company), Indiana, United States, Investments, expansion, Pennsylvania, Expanding, upgrade, Research Organization

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal

2 days ago talkbio0Tagged Keytruda, Metastatic to, Overall Survival, Triple Negative Breast Neoplasms, Trodelvy

Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival

Dupixent notches seventh disease approval with urticaria nod

2 days ago talkbio0Tagged Approved, Chronic Spontaneous Urticaria, Dupixent, seventh, United States Food and Drug Administration, Urticaria

Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

2 days ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

FDA clears its first prescription migraine app, from Click Therapeutics

7 days ago talkbio0Tagged click, Click Therapeutics, CT-132, first, Migraine Disorders, United States Food and Drug Administration

United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

1 week ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

1 week ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn

1 week ago talkbio0Tagged Acquisitions, adaptation, Artificial Intelligence, biotech downturn, growth opportunities, innovation, Landscapes, layoff, Precision Medicine, regulatory, strategic, Survival, trends qualifier

biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities